Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDH1 | P40925 | 1/20 | 0.41 |
| ▸ | MDH2 | P40926 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.41 |
| ▸ | IDH1 | O75874 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515494 | 0.92 | HPGD (0.43) | MCHR1MAPTGAAALDH1A1LMNA | |
| SCHEMBL4500860 | 0.90 | ALDH1A1 (0.39) | MCHR1IDH1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL4502903 | 0.88 | MAPT (0.38) | MAPTGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4511135 | 0.85 | ATF4 (0.47) | MCHR1MAPTGAAALDH1A1LMNA | |
| SCHEMBL4509399 | 0.84 | MCL1 (0.39) | GAAALDH1A1 | |
| SCHEMBL13674555 | 0.84 | CXCR3 (0.42) | MAPT | |
| SCHEMBL5547214 | 0.84 | CXCR3 (0.42) | MAPT | |
| SCHEMBL13674510 | 0.84 | ALDH1A1 (0.38) | MAPTGAAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4504293 | 0.83 | ALDH1A1 (0.41) | GAAALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL4512718 | 0.83 | ALDH1A1 (0.36) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | MDH1 511/4885MDH2 410/4885MCHR1 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.